← Back to Search

Device

CPAP + Medication + Oxygen for Obstructive Sleep Apnea (ExPRESSION Trial)

La Jolla, CA
Phase 2
Recruiting
Led By Christopher Schmickl
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ages 21-65 years old
Be older than 18 years old
Must not have
Other known untreated sleep fragmenting disorder, such as periodic limb movement disorder, or narcolepsy
Already on effective therapy and adherent to treatment for OSA
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will study people with Obstructive Sleep Apnea to try and understand why some people have it and how it affects them.

See full description
Who is the study for?
This trial is for men and women aged 21-65 with a physician's diagnosis of OSA, or suspected to have it, who are not active smokers/vapers and do not have uncontrolled high blood pressure, chronic lung disease requiring oxygen, recent hospitalization, heavy alcohol use, certain heart conditions, active cancer or other specific health issues. BMI must be between 20 - 35 kg/m2.Check my eligibility
What is being tested?
The study aims to understand why people develop Obstructive Sleep Apnea (OSA) and how this relates to the effectiveness of treatments like CPAP machines, eszopiclone medication for sleep aid, and supplemental oxygen therapy in managing symptoms such as sleepiness and high blood pressure.See study design
What are the potential side effects?
Possible side effects may include discomfort from wearing the CPAP device at night; dizziness, dry mouth or unpleasant taste from eszopiclone; and dry nasal passages from using supplemental oxygen.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 21 and 65 years old.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not been treated for any sleep disorders like narcolepsy.
 show original
Select...
I am following my treatment plan for sleep apnea.
 show original
Select...
I have been regularly taking Eszopiclone.
 show original
Select...
I can give my own consent and complete English-only study tasks.
 show original
Select...
I need extra oxygen or have high CO2 levels due to lung blockage.
 show original
Select...
I have had gastric bypass surgery.
 show original
Select...
I was hospitalized in the last 3 months.
 show original
Select...
I consume more than the recommended amount of alcohol nightly.
 show original
Select...
I have heart issues like untreated blocked arteries, chest pain, past heart attack or stroke, or heart failure.
 show original
Select...
My cancer is currently active.
 show original
Select...
I have had a stomach ulcer, esophageal varices, or bleeding in my digestive tract in the last 5 years.
 show original
Select...
I am allergic to the medication used in this study.
 show original
Select...
I have chronic liver or severe kidney disease.
 show original
Select...
I regularly take medications that can affect my breathing.
 show original
Select...
I have a psychiatric condition other than well-managed depression or anxiety.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Endothelial Dysfunction
Psychomotor Vigilance Test
Secondary study objectives
Beck Depression Index-II
Brief Pain Inventory (Short Form)
Diastolic Blood Pressure
+11 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Usual PAP StartExperimental Treatment2 Interventions
After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will remain untreated until they are set up with their clinically prescribed CPAP (typically takes about 8 weeks).
Group II: Early PAP StartExperimental Treatment3 Interventions
After two initial baseline overnight studies, and two experimental overnight studies during which subjects will receive Eszopiclone (2mg before bedtime) or oxygen (4L/min via nasal cannula for the duration of the time in bed) in random order, subjects will be set up with a loaner CPAP for 8 weeks to initiate therapy right away.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Eszopiclone
2005
Completed Phase 4
~4200
Continuous Positive Airway Pressure (CPAP)
2004
Completed Phase 3
~2880

Find a Location

Closest Location:Altman Clinical and Translational Research Institute Building· La Jolla, CA

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,211 Previous Clinical Trials
1,592,812 Total Patients Enrolled
Christopher SchmicklPrincipal InvestigatorPostdoc Fellow, Medicine
Atul Malhotra, MDPrincipal InvestigatorProfessor, Medicine
11 Previous Clinical Trials
705 Total Patients Enrolled

Media Library

Continuous Positive Airway Pressure (CPAP) (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04875364 — Phase 2
Obstructive Sleep Apnea Research Study Groups: Usual PAP Start, Early PAP Start
Obstructive Sleep Apnea Clinical Trial 2023: Continuous Positive Airway Pressure (CPAP) Highlights & Side Effects. Trial Name: NCT04875364 — Phase 2
Continuous Positive Airway Pressure (CPAP) (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04875364 — Phase 2
Obstructive Sleep Apnea Patient Testimony for trial: Trial Name: NCT04875364 — Phase 2
~55 spots leftby Jan 2027